Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.54 |
| ▸ | IDO1 | P14902 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HTR1E | P28566 | 1/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7428096 | 0.98 | MEN1 (0.55) | MEN1KMT2APKMCTDSP1IDO1 | |
| SCHEMBL25324799 | 0.90 | FFAR1 (0.51) | MEN1KMT2APKMCTDSP1IDO1 | |
| SCHEMBL11854684 | 0.89 | MEN1 (0.56) | MEN1KMT2APKMCTDSP1KDM4E | |
| SCHEMBL7194995 | 0.83 | PKM (0.56) | MEN1KMT2APKMCTDSP1IDO1 | |
| SCHEMBL1697227 | 0.81 | SLC6A2 (0.59) | — | |
| SCHEMBL2716196 | 0.81 | MEN1 (0.41) | MEN1KMT2APKMCTDSP1IDO1 | |
| SCHEMBL2085660 | 0.81 | MEN1 (0.58) | MEN1KMT2APKMCTDSP1IDO1 | |
| SCHEMBL2465315 | 0.81 | PKM (0.62) | MEN1KMT2APKMCTDSP1IDO1 | |
| SCHEMBL1005727 | 0.81 | MEN1 (0.54) | MEN1KMT2APKMCTDSP1IDO1 | |
| SCHEMBL3121803 | 0.81 | MEN1 (0.54) | MEN1KMT2APKMCTDSP1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518954-B2 | Inhibitors of folic acid-dependent enzymes | STOICESCU DAN (CH) | 2013-08-27 | — | — | US | disclosed |
| US-8247422-B2 | Use of condensed pyrimidine derivatives for the treatment of rheumatoid arthritis | STOICESCU DAN (CH) | 2012-08-21 | — | — | US | disclosed |
| EP-2117552-B1 | USE OF CONDENSED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | STOICESCU DAN (CH) | 2011-08-03 | — | — | EP | disclosed |
| US-7875716-B2 | Such as n-[4-[[2,4-diamino-6-pteridinyl)methyl]amino]benzoyl]pseudoglutamic ester; synthesis; efficacy; reduced renal toxicity and other adverse side effects; cancer | STOICESCU DAN | 2011-01-25 | — | — | US | disclosed |
| US-20100249141-A1 | NOVEL INHIBITORS OF FOLIC ACID-DEPENDENT ENZYMES | STOICESCU DAN | 2010-09-30 | — | — | US | disclosed |
| US-20100160329-A1 | USE OF CONDENSED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | STOICESCU DAN | 2010-06-24 | — | — | US | disclosed |
| US-7718660-B2 | Inhibitors of folic acid-dependent enzymes | STOICESCU DAN | 2010-05-18 | — | — | US | disclosed |
| EP-2117552-A1 | USE OF CONDENSED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | Stoicescu, Dan (CH) | 2009-11-18 | — | — | EP | disclosed |
| US-7560586-B2 | Acid and ester compounds and methods of using the same | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-14 | — | — | US | disclosed |
| US-7560586-B2 | Acid and ester compounds and methods of using the same | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-14 | — | — | US | disclosed |
| WO-2007020277-A2 | CONDENSED PYRIMIDINE DERIVATIVES AS INHIBITORS OF FOIC ACID-DEPENDENT ENZYMES | STOICESCU DAN (CY) | 2007-02-22 | — | — | WO | disclosed |
| EP-1754484-A1 | Condensed pyrimidine derivatives as inhibitors of foic acid-dependent enzymes | Stoicescu, Dan (CY) | 2007-02-21 | — | — | EP | disclosed |
| EP-1575495-A2 | COMPOUNDS AND METHODS | SmithKline Beecham Corporation (US) | 2005-09-21 | — | — | EP | disclosed |
| US-20050113580-A1 | Amide compounds and methods of using the same | SMITHKLINE BEECHAM CORP | 2005-05-26 | — | — | US | disclosed |
| WO-2003082205-A2 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
| US-5643904-A | Substituted hexahdryoazepinones and tetrahydrobenzazepinones | PFIZER INC. (US) | 1997-07-01 | — | — | US | disclosed |
| US-5484917-A | FOR TREATMENT AND PREVENTION OF GASTROINTESTINAL DISORDERS, PAIN AND ANXIETY | PFIZER INC. (US) | 1996-01-16 | — | — | US | disclosed |
| EP-0625145-A1 | 3-PHENYLUREIDO-AZEPIN-2-ONES AND -BENZAZEPIN-2-ONES USEFUL AS CHOLECYSTOKININ ANTAGONISTS | PFIZER INC. (US) | 1994-11-23 | — | — | EP | disclosed |
| WO-1993015059-A1 | 3-PHENYLUREIDO-AZEPIN-2-ONES AND -BENZAZEPIN-2-ONES USEFUL AS CHOLECYSTOKININ ANTAGONISTS | PFIZER INC. (US) | 1993-08-05 | — | — | WO | disclosed |
| CN-1074903-A | The six hydrogen azepine ketone and the tetrahydro benzo azepine ketone that replace | PFIZER (US) | 1993-08-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160329-A1 | USE OF CONDENSED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES | CCR8, HRH4, CXCL8 | MEN1 3908/4885KMT2A 2040/4885PKM 4669/4885 |
| US-20050113580-A1 | Amide compounds and methods of using the same | NR1H2, NR1H3, PPARA | MEN1 4182/4885KMT2A 975/4885PKM 2302/4885 |
| US-20100249141-A1 | NOVEL INHIBITORS OF FOLIC ACID-DEPENDENT ENZYMES | FOLR2, FOLR1, DHFR | MEN1 2304/4885KMT2A 1697/4885PKM 4028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.